Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8.  However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ] The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances … Continue reading AHA names PCSK9 inhibitor evolocumab as a top advance in heart disease